Clinical Research Directory

Inclusion Criteria: 1. at least 18 years of age; 2. Histologically or cytologically confirmed metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC); 3. Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically.( EGFR L858R or Del 19 with/without T790M ) 4. Imaging (MR/CT) confirmed untreated brain metastases before Furmonertinib initiation; 5. Organ function is compatible with oral Furmonertinib therapy (investigator determination based on real-world practice); 6. Life expectancy ≥12 weeks before Fumonertinib initiation; 7. ECOG PS of 0 to 2; 8. Sign the informed consent form. Exclusion Criteria: 1. Any Third-Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) before Furmonertinib initiation; 2. Known hypersensitivity to Furmonertinib or its excipient components; 3. Simultaneous systemic chemotherapy or WBI; 4. The time from the treatment with any other investigational product or its analogue before Furmonertinib initiation does not exceed 5 half-lives of the drug or 14 days, whichever is longer; 5. Any evidence of severe or uncontrolled systemic diseases; 6. Presence of any disease that may strongly interfere with oral drug absorption; presence of any factor that contributes to QTc prolongation or increased risk of arrhythmia; presence of interstitial pneumonitis.